ABOUT US

First Analysis has a four-decade record of serving emerging growth companies, established industry leaders, and institutional investors in emerging high-growth tech-driven segments, both through its venture capital investments and through First Analysis Securities Corp. (FASC), which provides investment banking and related services. FASC is a FINRA-registered broker-dealer and member SIPC. First Analysis’s integrative research process underpins all its efforts, combining 1) dynamic investment research on thousands of companies with 2) thousands of relationships among executives, investors, and other key participants in our focus areas, yielding a deep, comprehensive understanding of each sector’s near-term and long-term potential.

FIRST ANALYSIS NEWS
First Analysis portfolio company VisiQuate has been acquired by Accel-KKR
Accel-KKR has acquired First Analysis portfolio company VisiQuate, a provider of advanced revenue cycle analytics, AI-powered workflow and automation solutions. The strategic partnership leverages Accel-KKR's extensive resources and strategic expertise to accelerate product innovation and expand VisiQuate's team.
October 07, 2024
Accel-KKR has acquired First Analysis portfolio company VisiQuate, a provider of advanced revenue cycle analytics, AI-powered workflow and automation solutions. The strategic partnership leverages Accel-KKR's extensive resources and strategic expertise to accelerate product innovation and expand VisiQuate's team.
October 07, 2024
First Analysis invests in Applied StemCell, a leading cell and gene therapy CRO/CDMO
First Analysis, a leading venture capital investor, has made a new investment in Applied StemCell (ASC), a contract development and manufacturing organization (CDMO) specializing in tailored cell and gene therapy solutions. First Analysis co-invested in ASC alongside QHP Capital.
July 16, 2024
First Analysis, a leading venture capital investor, has made a new investment in Applied StemCell (ASC), a contract development and manufacturing organization (CDMO) specializing in tailored cell and gene therapy solutions. First Analysis co-invested in ASC alongside QHP Capital.
July 16, 2024
First Analysis invests in Sware, provider of FDA-mandated computer system validation automation for GxP systems and release testing
First Analysis, a leading venture capital investor, has made a new investment in Sware, which provides a complete software validation solution for innovative life sciences companies. The investment will be used to bolster research and development of Sware's computer systems validation (CSV) platform, Res_Q, to further streamline processes with artificial intelligence (AI), and to expand the company's sales team so it can bring the platform to more organizations struggling with validation debt.
June 07, 2024
First Analysis, a leading venture capital investor, has made a new investment in Sware, which provides a complete software validation solution for innovative life sciences companies. The investment will be used to bolster research and development of Sware's computer systems validation (CSV) platform, Res_Q, to further streamline processes with artificial intelligence (AI), and to expand the company's sales team so it can bring the platform to more organizations struggling with validation debt.
June 07, 2024

CONTACT INFORMATION

One South Wacker Drive
Suite 3900
Chicago, Illinois 60606
312-258-1400

©2024 by First Analysis Corporation.
One South Wacker Drive
  ·  
Suite 3900
  ·  
Chicago, IL 60606
  ·  
312-258-1400